# Mesoblast (MESO) — News MESO · NASDAQ · Stock Canonical page: https://www.lighthorse.io/tickers/meso/news ## Recent headlines - [Mesoblast 1Q ryoncil net rev. $28M](https://www.ainvest.com/news/mesoblast-1q-ryoncil-net-rev-28m-2610) — AInvest Wire, Oct 15, 2026 Mesoblast Limited (ASX:MSB; Nasdaq:MESO) reported first-quarter net revenue of $28 million from its cell therapy products, reflecting continued growth in the commercialization of its allogeneic cellular medicines. The company has established itself as a global leader in the development of… - [H&M currently investigating, press office says](https://www.ainvest.com/news/investigating-press-office-2610) — AInvest Wire, Oct 14, 2026 H&M is currently investigating multiple allegations concerning its business practices, according to the company’s press office. The ongoing inquiries include claims of unethical labor conditions in factories , as reported by the UK’s Daily Mail. The investigation follows allegations of sweatshop… - [Gapack: Trading in shares will remain suspended](https://www.ainvest.com/news/gapack-trading-shares-remain-suspended-2610) — AInvest Wire, Oct 5, 2026 Trading in shares of Gapack has remained suspended as of October 5, 2026, with no indication of a near-term resumption. The suspension, initially implemented to allow for a review of the company’s financial disclosures and operational status, continues while regulatory authorities and the company… - [Mesoblast gets FDA OK for Ryoncil's new potency assay](https://www.ainvest.com/news/mesoblast-fda-ryoncil-potency-assay-2609) — AInvest Wire, Sep 24, 2026 Mesoblast Limited (ASX:MSB) has received approval from the U.S. Food and Drug Administration (FDA) for a new potency assay for Ryoncil, its autologous bone marrow-derived stem cell therapy used in the treatment of complex perianal fistulas in patients with Crohn’s disease. The new assay is intended… - [MesoBlast Limited - FDA approves new potency assay for commercial ryoncil](https://www.ainvest.com/news/mesoblast-limited-fda-approves-potency-assay-commercial-ryoncil-2609) — AInvest Wire, Sep 23, 2026 MesoBlast Limited has announced that the U.S. Food and Drug Administration (FDA) has approved a new potency assay for the commercial production of Ryoncil, the company’s flagship product. This development follows a Type A meeting with the FDA, during which key aspects were reviewed and validated .… --- Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express. This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness. Data provided by [AInvest](https://www.ainvest.com).